PATENT CLAIM ANALYSIS

Application Number: 16078266
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-05
Patent Classification: ["514", "04400A"]

Abstract:
The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.

Claim (Index 3):
The method of  claim 2 , wherein said AAV is AAV9.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 96.0
- Lexical Diversity: 1.92308
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13504614', '15340721', '14909854', '12447558', '13936728']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8160729400792183
- 35 USC 102 Novelty (BERT): 0.5506273072532114
- Combined Prediction Score: 0.7895283767966177
- Mean Citation Score: 371.46888
- Max Citation Score: 415.7373
- Similarity Product: 332.584442943424

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test